SANUWAVE Health, Inc. has announced that the FDA has issued its decision on the de novo submission for the dermaPACE System. Their decision, dated December 28, 2017, permits the marketing of the dermaPACE System as a Class II medical device used for the treatment of Diabetic Foot Ulcers (DFU) in the U.S., the world’s largest medical device market.